ClinicalTrials.gg
TerminatedNCT06487559Updated Oct 21, 2026

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

A Phase 1 interventional study of Livmoniplimab and Budigalimab in Hepatocellular Carcinoma (HCC), sponsored by AbbVie. Terminated at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Strategic considerations
Updated Oct 21, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Carcinoma, Hepatocellular by AbbVie — 1 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · AbbVie.

Enrollment
10th of 10
3 · median 110
Started
2024
with 1 other
Phase 1
7 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by AbbVie, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 1, and was the 10th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

1 of the 10 studies in Carcinoma, Hepatocellular by AbbVie is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by AbbVie, or all of them as a file.
02

Study summary

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC).

Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab in combination with budigalimab (fixed dose). Stage 2 is dose expansion. There are 2 treatment arms in stage 2 and participants will receive Livmoniplimab in combination with budigalimab in multiple doses. Approximately 20 adult participants will be enrolled in the study across 15 sites in China.

In part 1 (dose escalation), participants will be intravenously infused with escalating doses of livmoniplimab in combination with budigalimab every 3 weeks. In part 2 (dose expansion), participants will be intravenously infused with livmoniplimab in combination with budigalimab in multiple doses every 3 weeks. The estimated duration of the study is up to 2 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • Hepatocellular Carcinoma (HCC)
  • Livmoniplimab
  • ABBV-151
  • budigalimab
  • ABBV-181
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or and/or unresectable HCC
  • A
  • Barcelona Clinic Liver Cancer stage B or C
  • (ECOG) Perfromance Status of 0-1
  • Received an in 1L HCC treatment regimen
  • Adequate hematologic and end-organ function

Exclusion criteria

Exclusion Criteria:

  • Symptomatic, untreated, or actively progressing central nervous system (CNS) as outlined in the protocol.
  • History of other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%).
  • History of , immune deficiency, or inflammatory disorders including, but not limited to, inflammatory bowel disease, systemic lupus erythematosus, sarcoidosis, Wegener syndrome, rheumatoid arthritis, antiphospholipid antibody syndrome, Guillain-Barre syndrome, or multiple sclerosis
  • History of conditions such as but not limited to the following: renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that in Investigator's opinion, would adversely affect the subject's participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Stage 1: Cohort 1 Livmoniplimab + Budigalimab Dose A

    Participants will receive livmoniplimab Dose A in combination with budigalimab every 3 weeks for approximately 2 years.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Stage 2: Cohort 2 Livmoniplimab + Budigalimab Dose B

    Participants will receive livmoniplimab Dose B in combination with budigalimab every 3 weeks for approximately 2 years.

    Drug: Livmoniplimab · Drug: Budigalimab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AE)

    An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 2 Years

  2. Number of Participants with Dose-Limiting Toxicities (DLT)

    DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

    Time frame: Up to Approximately 2 Years

  3. Maximum Plasma Concentration (Cmax) of Livmoniplimab and Budigalimab

    Maximum Plasma Concentration (Cmax) of livmoniplimab and Budigalimab

    Time frame: Up to Approximately 2 Years

  4. Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab and Budigalimab

    AUC of livmoniplimab and Budigalimab

    Time frame: Up to Approximately 2 Years

Secondary outcomes

  1. Best Overall Response (BOR) for Participants with Confirmed CR/PR per RECIST v1.1

    Defined as achieving either confirmed CR or confirmed PR per RECIST v1.1 as assessed by the investigator.

    Time frame: Up to Approximately 2 Years

  2. Duration of response (DOR) for Participants with Confirmed CR/PR

    Defined as the time from the participant's initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause.

    Time frame: Up to Approximately 2 Years

  3. Progression-free survival (PFS)

    Defined as the time from the participant's first dose of study drug until radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first.

    Time frame: Up to Approximately 2 Years

  4. Overall survival (OS)

    Defined as the time from the participant's first dose of study drug until death from any cause.

    Time frame: Up to Approximately 2 Years

  5. Antidrug Antibody (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: Up to Approximately 2 Years

  6. Neutralizing Antidrug Antibody (nADA)

    Incidence and concentration of neutralizing anti-drug antibodies.

    Time frame: Up to Approximately 2 Years

07

Study locations

11 sites
  • Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928
    Beijing, Beijing Municipality 100069, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443
    Fuzhou, Fujian 350012, China
  • Sun Yat-Sen University Cancer Center /ID# 262092
    Guangzhou, Guangdong 510060, China
  • Nanfang Hospital of Southern Medical University /ID# 262091
    Guangzhou, Guangdong 510515, China
  • Harbin Medical University Cancer Hospital /Id# 262070
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital /ID# 262098
    Zhengzhou, Henan 450008, China
  • Hubei Cancer Hospital /ID# 262030
    Wuhan, Hubei 430079, China
  • The Second Affiliated Hospital of Nanchang University /ID# 262085
    Nanchang, Jiangxi 330008, China
  • Liaoning Cancer Hospital & Institute /ID# 268023
    Shenyang, Liaoning 110042, China
  • Zhongshan Hospital Fudan University /ID# 262135
    Shanghai, Shanghai Municipality 200032, China
  • Zhejiang Cancer hospital /ID# 262046
    Hangzhou, Zhejiang 310022, China
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2024 to primary completion in Sep 2026, 24 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 5, 2024
StartActual
Sep 11, 2024
Primary completionActual
Sep 18, 2026was Feb 2027
CompletionActual
Sep 18, 2026was Feb 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Strategic considerations
changed Oct 21, 2026
Primary completion
Feb 2027→Sep 18, 2026 (actual)
Oct 21, 2026
Study completion
Feb 2027→Sep 18, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Active, not recruiting→Terminated
    Why stopped Strategic considerations
    Primary completion Feb 2027→Sep 18, 2026 (now actual)
    Study completion Feb 2027→Sep 18, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06487559
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Sep 11, 2024
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Oct 21, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Livmoniplimab · Budigalimab

Start the discussion